Minerva Neurosciences (NASDAQ:NERV) Rating Increased to Hold at Wall Street Zen
by Doug Wharley · The Cerbat GemWall Street Zen upgraded shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) from a sell rating to a hold rating in a research report report published on Saturday.
A number of other research firms have also recently weighed in on NERV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a report on Monday, December 29th. HC Wainwright lowered their target price on Minerva Neurosciences from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, November 6th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Minerva Neurosciences presently has a consensus rating of “Reduce” and a consensus price target of $4.00.
Get Our Latest Stock Analysis on NERV
Minerva Neurosciences Stock Performance
Shares of NERV opened at $6.60 on Friday. The firm has a fifty day moving average of $4.87 and a 200-day moving average of $3.74. The company has a market cap of $285.58 million, a price-to-earnings ratio of -3.57 and a beta of -0.22. Minerva Neurosciences has a 1 year low of $1.15 and a 1 year high of $12.46.
Institutional Trading of Minerva Neurosciences
Hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC acquired a new stake in shares of Minerva Neurosciences in the fourth quarter valued at $36,000. State Street Corp lifted its holdings in Minerva Neurosciences by 45.4% in the 4th quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 7,500 shares during the last quarter. Apella Capital LLC boosted its position in shares of Minerva Neurosciences by 87.8% during the 3rd quarter. Apella Capital LLC now owns 39,314 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 18,375 shares in the last quarter. Millennium Management LLC bought a new position in shares of Minerva Neurosciences during the 4th quarter valued at about $554,000. Finally, Renaissance Technologies LLC grew its stake in shares of Minerva Neurosciences by 28.1% in the 4th quarter. Renaissance Technologies LLC now owns 149,200 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 32,700 shares during the last quarter. Institutional investors own 34.56% of the company’s stock.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.
The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.